So far, Several reports concluded that CD200 expression is also associated with the progression of various solid cancers, such as bladder cancer, lung cancer, breast cancer prostate carcinoma, cutaneous squamous cell carcinoma and acute myeloid leukemia (Kretz-Rommel et al., 2007; Lawlor et al., 2019; Aref et al 2020). This evidence concerns the gene CD200 and prostate carcinoma.